Drug Trial Radar · NCT04586478
Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
Last checked: Nov 19, 2026Latest source record: Feb 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Oct 26, 2020
Primary completion
Mar 30, 2024
Study completion Sep 30, 2025
Sponsor
- Lead sponsor
- Juventas Cell Therapy Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 14, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is a Phase II, single-arm, open-label, single-dose clinical trial, and its primary objective is to evaluate the efficacy and safety of CNCT19 Cell Injection in the treatment of relapsed or refractory NHL.
Conditions
- Non-Hodgkin's Lymphoma
Interventions
single dose of CNCT19Biological
Dose: 2.00 x 10\^8 CNCT19 Cell Injection via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Remission Rate (ORR), which includes Complete Remission (CR) and Partial Remission (PR)Time frame: At 3 months after infusion
Locations
17 sites in 1 country. Site status is shown where the registry gives one.
Beijing Boren Hospital
Beijing, Beijing Municipality, China · Recruiting
Beijing Cancer Hospital
Beijing, Beijing Municipality, China · Recruiting
Peking University Third Hospital
Beijing, Beijing Municipality, China · Recruiting
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China · Recruiting
Xinqiao Hospital of TMMU
Chongqing, Chongqing Municipality, China · Recruiting
Guangdong Provincial Peoples' Hospital
Guangzhou, Guangdong, China · Recruiting
SunYat-Sen University Cancer Center
Guangzhou, Guangdong, China · Recruiting
Henan Cancer Hospital
Zhengzhou, Henan, China · Recruiting
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China · Recruiting
Tongji Hospital, Tongji Medical College of HUST
Wuhan, Hubei, China · Recruiting
Qilu Hospital of Shandong University
Jinan, Shandong, China · Recruiting
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China · Recruiting
Tongji Hospital of Tongji University
Shanghai, Shanghai Municipality, China · Recruiting
West China Hospital,Sichuan University
Chengdu, Sichuan, China · Recruiting
Institute of Hematology & Blood Diseases Hospital
Tianjin, Tianjin Municipality, China · Recruiting
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China · Recruiting
The First Affiliated Hospital, Zhejiang University school of Medicine
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.